CPI-1189 is primarily investigated for its potential therapeutic applications in the field of neurodegenerative diseases and inflammation. It has shown promise in preclinical studies for its neuroprotective properties, particularly in conditions like Alzheimer's disease and Parkinson's disease. The compound is believed to modulate inflammatory pathways and reduce oxidative stress, which are key factors in the progression of these disorders. Additionally, CPI-1189 has been explored for its potential to mitigate cognitive decline and improve neuronal function. Research is ongoing to further understand its efficacy and safety profile in clinical settings.